Find participating medical centers and current study status in each of them

    Find participating medical centers

    A phase I, open-label, single-dose randomized, two-period crossover study to evaluate the relative bioavailability of single oral doses of two different formulations of divarasib (GDC-6036; 200-mg tablet and 400-mg tablet) in healthy subjects

    • Healthy Volunteers